As another Smith & Singer specialist exits, one small-time collector is hoping for a tidy return from a print bought at Sydney’s Museum of Contemporary Art store.
Mohammad Haskali
Mohammad Haskali gained his Bachelor’s degree in analytical chemistry in 2008 from Victoria University (Australia). In 2014, Mohammad has submitted his PhD thesis from his research at the University of Melbourne in collaboration with the Peter MacCallum Cancer Centre. In his graduate studies, Mohammad synthesized novel peptide and improved their radiolabelling procedures. Furthermore, he succeeded in automating his procedures with either the TRACERlab FX
FN module or the newly developed iPHASE Flexlab dual reactor. From January 2013 to October 2014, Mohammad worked at Cyclotek Pty. Ltd., Australia’s leading production facility for
18F-labeled radiopharmaceuticals. His major role in the company was in GMP validation of new
U S FDA Expands Approval of Pfizer s LORBRENA as First-Line Treatment for ALK-Positive Metastatic Lung Cancer wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.
Approval is based on CROWN trial, which showed a 72% reduction in risk of progression or death for treatment with LORBRENA vs. XALKORI ® The U.S. Food and Drug Administration approved Pfizer Inc.’s supplemental New Drug Application for LORBRENA ® expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase -positive non-small cell lung cancer . LORBRENA is now indicated for … Approval is based on CROWN trial, which showed a 72% reduction in risk of progression or death for treatment with LORBRENA vs. XALKORI ® The U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s (NYSE: PFE) supplemental New Drug Application (sNDA) for LORBRENA